Vilon Evidence Guide
Evidence for Vilon is too preliminary to support a research protocol with confidence. All data originates from a single Russian research group with no independent replication. The regulatory and peer-review context differs from international standards. NAD+ precursors are a vastly better-evidenced starting point for Anti-Aging & Longevity research.
Our Take
Evidence for Vilon is too preliminary to support a research protocol with confidence. All data originates from a single Russian research group with no independent replication. The regulatory and peer-review context differs from international standards. NAD+ precursors are a vastly better-evidenced starting point for Anti-Aging & Longevity research.
- Evidence context
- Khavinson peptide immunology research (Russian data only)
- Evidence grade
- Level D
- Confidence
- Low
- Reference context
- Reported research reference: No established human protocol outside Russian clinical context
Benefits and Evidence
- Thymic Function Modulation: Level D, mostly non-human evidence - Khavinson & Morozov (2003, Neuroendocrinol Lett) showed Vilon (Lys-Glu) at 10 ng/mL doubled thymulin production in cultured thymic epithelial cells from aged rats; in vivo, 10 ug/kg daily for 5 days partially restored thymic cortex-to-medulla ratio and increased thymocyte proliferation by 45% in 24-month-old rats.
- T-cell Differentiation: Level D, mostly non-human evidence - Cell culture studies demonstrate Vilon promotes CD4+ and CD8+ T-cell differentiation markers and enhances lymphocyte responsiveness to mitogens.
Side Effects and Warnings
- Generally well-tolerated in available studies
- Mild gastrointestinal discomfort (rare)
- Possible immune stimulation effects
- Research is limited to Russian institutions with minimal independent replication
- No controlled human clinical trials have been published
- Theoretical risk of immune overactivation in autoimmune conditions
- Mechanism of DNA interaction by such a small peptide remains controversial
Research Dosage References
- <strong>Sublingual</strong> - 100-500 mcg - Once or twice daily - Sublingual administration is common in bioregulator protocols. No clinically validated dosing exists.
- <strong>Oral</strong> - 500 mcg-1 mg - Once daily - Oral bioavailability of dipeptides is generally limited. Enteric coating may improve absorption.
Mechanism of Action
Vilon (KE dipeptide) penetrates cell nuclei where it binds specific DNA sequences in gene promoter regions, particularly in immune cells. It has been shown to interact with the histone H1 linker domain, modulating chromatin structure and accessibility. In thymocytes, it upregulates genes involved in T-cell differentiation (CD3, CD4, CD8 markers) and thymulin production. In aged tissues, it reactivates silenced immune genes through epigenetic mechanisms, potentially restoring aspects of thymic function that decline with age.
Legal Status
Unregulated research peptide; available as dietary supplement in Russia.
Primary Sources
- Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Bulletin of Experimental Biology and Medicine, 2012.
- Molecular aspects of biological activity of short peptides. Advances in Gerontology, 2014.
Quick Answers
Where is the strongest evidence for Vilon?
Evidence for Vilon is too preliminary to support a research protocol with confidence. All data originates from a single Russian research group with no independent replication. The regulatory and peer-review context differs from international standards. NAD+ precursors are a vastly better-evidenced starting point for Anti-Aging & Longevity research. Evidence context: Khavinson peptide immunology research (Russian data only).
What are the main side effects of Vilon?
Vilon side effects and warning signals include Generally well-tolerated in available studies, Mild gastrointestinal discomfort (rare), Possible immune stimulation effects, Research is limited to Russian institutions with minimal independent replication, and No controlled human clinical trials have been published.
What evidence level is Vilon?
Vilon is rated Level D; the listed research status is Early Research.